High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Optimal ribavirin dosages are essential in achieving SVR (sustained virological response).
Several studies have shown higher SVR rates in patients receiving higher doses of ribavirin.
Therefore we propose a randomized controlled open label multicenter trial to investigate
wether high (25-29mg/kg) dose ribavirin can improve outcome in patients in infected with
hepatitis C virus genotype 1 or 4 compared to standard dose (12-15mg/kg).